Please assess the completion status of the following clinical trial:

Trial Title: HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Active CLL (as defined by the National Cancer Institute Working Group)~* Patients must have received at least one prior therapy for CLL and have been treated with a nucleoside analogue.~* Recruitment will be limited to those with an ECOG performance status of 2 or less.~Exclusion Criteria:~* Patients who are pregnant or breastfeeding~* Patients with a history of autoimmune cytopenias~* Patients with platelets \< 50 x 109/L or an absolute neutrophil count \< 1.5X109/L~* Patients with hepatic disease or an AST/ALT 6x above the upper limit of normal~* Patients with a calculated creatinine clearance \< 30 ml/min using the Cockroft and Gault formula~* Patients with a history of pancreatitis~* Patients who are receiving drugs that affect VPA protein binding or metabolism~* Patients with active infection, HIV or active viral hepatitis~* Patients with active secondary malignancy or who have central nervous system involvement with CLL~* Patients diagnosed with more an aggressive lymphoproliferative disorder such as Richter's transformation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).